“…Median OS, from begin of treatment: 50 weeks (95% CI: 39–61 weeks) 3. 46% According to WHO (n = 44) Related to WBH: Mucosal herpes infections: n = 17, responsive to acyclovir Pressure scores (grade 1 and 2): n = 3 Transient cardiac arrhythmias with ECG signs of myocardial ischaemia (grade 3): n = 5 Comparison Group A and B: Haematological toxicity : In cycles with WBH: grade 0: 91.7%, grade 1: 2.6%, grade 2: 4.4%, grade 3: 1.2% In cycles without WBH: grade 0: 93.7%, grade 1: 1.6%, grade 2: 2.8%, grade 3: 1.9% Gastrointestinal toxicity : In cycles with WBH: grade 0: 82.6%, grade 1: 11%, grade 2: 4.9%, grade 3: 1.5% In cycles without WBH: grade 0: 85.5%, grade 1: 9.6%, grade 2: 3.7%, grade 3: 1.2% Peripheral neurotoxicity : In cycle with WBH: grade 0: 39.2%, grade 1: 40.8%, grade 2: 18.5%, grade 3: 1.5% In cycle without WBH: grade 0: 49.0%, grade 1: 35.0%, grade 2: 14.7%, grade 3: 1.4% Fatigue syndrome : In cycle with WBH: grade 3: 20%, grade 4: 5% In cycle without WBH: grade 3: 6%, grade 4: 3% Related to Oxaliplatin: Most frequent: mild neurosensory toxicities: 68% Severe sensory neuropathy with functional impairment due to loss of sensitivity in fingertips and soles of feet towards end of therapy: n = 1 Almost all patients reported neurotoxicity to be less pronounced in cycles combined with WBH | Gerke et al [ 49 ] | Arm A : ECC-WBH (Level One) + CTx (n = 9) Arm B: rWBH (Aquatherm) + CTx (n = 18) Arm C: CTx alone (n = 16) Type of cancer: Sarcoma Duration target temp. per session: 41.8 °C for 1 h Number of treatments: 4–6 courses Period of time: January–December 1995 | 1. |
…”